1. Patients launch a $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
The Chronic Fatigue Initiative and Interview with Mady Hornig
In a follow-up article to the recent IACFS/ME conference presentation in San Francisco, and after speaking at length with Dr. Mady Hornig, 'searcher' delves deeper into the impressive work being completed by the Chronic Fatigue Initiative, and focuses in on those cytokine results ...
Discuss the article on the Forums.

Interactions between APOBEC3 proteins, HIV-1, and XMRV at NIH on April 1st

Discussion in 'XMRV Research and Replication Studies' started by George, Mar 24, 2010.

  1. George

    George Guest

    EVENT DESCRIPTION Event Type: Seminar (This is an NIH Science event)

    Title: Interactions between APOBEC3 proteins, HIV-1, and XMRV

    Description: Current advances in our understanding of intracellular immunity conferred by host cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) and the mechanism by which the virally encoded virion infectivity factor (Vif) protein induces their proteasomal degradation provide fresh opportunities for the development of novel antiviral treatments. Interestingly, the Vif A3G and Vif A3F interactions that overcome this host defense mechanism are structurally distinct and provide two potential targets for antiviral drug development.

    Recent studies have reported the first gammaretrovirus that infects humans, named xenotropic murine leukemia virus-related virus (XMRV). XMRV was isolated from human prostate cancer tissue and from activated CD4+ T cells and B cells of patients with chronic fatigue syndrome, suggesting an association between XMRV infection and these two disease states. Since APOBEC3G (A3G) and APOBEC3F (A3F), which are potent inhibitors of the murine leukemia virus and Vif-deficient human immunodeficiency virus type 1 (HIV-1), are expressed in human CD4+ T cells and B cells, we sought to determine how XMRV evades suppression of replication by APOBEC proteins. We found that XMRV infectivity is potently inhibited by A3G and A3F, and to a lesser extent, by murine APOBEC3. Overall, these results suggest that the establishment of XMRV infection in patients may be dependent on infection of A3G/A3F-deficient cells and that prostate epithelial cells may provide an ideal target for XMRV replication and spread.

    Series Name: Virology Interest Group

    Event URL: http://sigs.nih.gov/VIG/Pages/Meetings.aspx

    Videocast: Event will not be videocast

    Special Instructions: To arrange sign language interpretation for an event go to the Office
    of Research Services (ORS) Interpreting Service Requests web page. EVENT DATE/TIME Date/Time: Thursday, April 01, 2010 12:00pm - 1:00pm

    EVENT SPEAKER(S) Name: Vinay K. Pathak
    Title: Ph.D. Organization: Viral Mutation Section, HIV Drug Resistance Program, CCR, NCI City/Province: Frederick State: Maryland

    EVENT SPONSOR(S) Organization(s): [NIH] Virology Interest Group
    EVENT LOCATION Location: On the main NIH Campus Building: Building 4 Room: 433 Street Address: 4 Center Drive City: Bethesda State: Maryland Zip Code: 20892
    EVENT CONTACT(S) Name: Gaelle Kolb E-mail: kolbg@mail.nih.gov Phone: 301-443-5582
  2. George

    George Guest

    Meet Vinney, he gets four paws up. (grins)

    Our Science Pathak Website



    Vinay K. Pathak, Ph.D.


    [​IMG] [​IMG] [​IMG] [​IMG] HIV DRP Retroviral Replication Laboratory
    Head, Viral Mutation Section Senior Investigator [​IMG] Building 535
    Room 334
    Frederick, MD 21702-1201 [​IMG] Phone:
    301-846-1710 Fax:
    301-846-6013 E-Mail:
    pathakv@mail.nih.gov [​IMG] Link:
    Other Homepage Biography

    Dr. Vinay K. Pathak received his B.A. in Biology from the University of California, Los Angeles, in 1979. He obtained his M.S. in Comparative Pathology in 1983 from the University of California, Davis, for characterization of mouse mammary tumor virus proviral integration sites near the int1 and int2 loci in mammary tumors and hyperplastic tissues in Dr. Robert Cardiff's laboratory. He received his Ph.D. for work on characterization of the eukaryotic protein synthesis initiation factors eIF-2a and eIF-2b in Dr. John W.B. Hershey's laboratory at the University of California, Davis, in 1988. He was a postdoctoral fellow under the guidance of Dr. Howard Temin from 1988 to 1991, where he determined the in vivo forward mutation rate of spleen necrosis virus and characterized the nature of mutations that arise during retroviral replication. In 1991, Dr. Pathak became an Assistant Professor in the Department of Biochemistry and the Mary Babb Randolph Cancer Center at West Virginia University. He was promoted to Associate Professor with tenure in 1998. He joined the National Cancer Institute in 1999 as Senior Investigator and Head of the Viral Mutation Section in the HIV Drug Resistance Program. Dr. Pathak was appointed as Guest Editor for the HIV Drug Resistance special issue of Viruses, which will be published in October 2009. He is also an Adjunct Professor at West Virginia University.
  3. Gerwyn

    Gerwyn Guest

    cell cell transfer is another way of doing it

See more popular forum discussions.

Share This Page